




The relative strengths and weaknesses of Array Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Array Biopharma INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Array Biopharma INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 141% points.

The company's Economic Capital Ratio, given in the ranking table, is 195%, being 68% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	191,047
Cost of Goods Sold	44,392
Intangible Assets	0
Liabilities, Current	42,424
Liabilities, Non-Current	113,130
Other Assets	2,110
Other Compr. Net Income	3.0
Other Expenses	0
Other Liabilities	0
Other Net Income	87,727
Other Revenues	51,909
Property and Equipment	5,050
Research and Development	54,442
Selling, General and Administrative Expense	31,433

Output Variable	Value in 1000 USD
Assets	198,207
Liabilities	155,554
Expenses	130,267
Revenues	51,909
Stockholders Equity	42,653
Net Income	9,369
Comprehensive Net Income	9,370
BaseVar	311,834
ECR before LimitedLiability	58%
Economic Capital Ratio	195%